US FDA accepts Glenmark’s IND application for GRC 54276 to proceed with Phase 1/2 clinical study for…
GRC54276 is an orally available, small molecule hematopoietic progenitor kinase 1 (HPK1) inhibitor developed by Glenmark
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.